Pigs were chosen deliberately. As a biomedical model, swine share striking anatomical and metabolic similarities with humans, particularly in cardiovascular physiology, body fat distribution, and digestive function. Human diet studies are notoriously difficult to control, because participants cheat, under-report, and vary wildly in adherence. Fifteen post-pubertal, non-pregnant, non-lactating gilts, Landrace by Yorkshire crosses averaging around 170 kilograms, were individually penned and paired by weight before being randomly assigned to one of two diets. Seven animals received a conventional, nutrient-balanced maintenance ration built around corn, while eight received a low-carbohydrate, high-fat formulation in which beef tallow supplied the energy normally delivered by grain. Soybean hulls were added to the high-fat diet to match the physical consistency of the control ration, and both diets were formulated to meet National Research Council requirements for swine of this age, sex, and reproductive stage.

The laboratory analysis confirmed the diets differed dramatically. The control diet contained roughly 3.3 percent crude fat and nearly 69 percent non-fiber carbohydrate on a dry matter basis, while the experimental diet contained 22.5 percent crude fat and only about 15.6 percent non-fiber carbohydrate, with neutral detergent fiber soaring to more than 44 percent thanks to the soy hulls. Interestingly, the calculated gross energy of the two rations diverged: the control diet provided approximately 3,993 kilocalories per kilogram, while the high-fat formulation came in at 3,448 kilocalories per kilogram, a discrepancy the authors attribute largely to the indigestible fiber fraction used to dilute the diet. Both rations were fed daily at 1.75 percent of each animal’s body weight, and feed refusals were weighed to calculate actual intake.

The results on body composition were the study’s most eye-catching finding. Control gilts gained weight steadily across the trial, ending roughly seven percent heavier than they started, while the high-fat group maintained a nearly constant body weight throughout. More striking was what happened beneath the skin. Measured by ultrasound adjacent the tenth thoracic vertebra, subcutaneous fat depth fell by 17.7 percent in the high-fat animals over 32 days, while control animals showed a 14 percent increase. At slaughter, the differences inside the body were even more dramatic: control gilts carried 1.74 times more visceral fat, the metabolically dangerous internal belly fat, than their high-fat counterparts, 2,660 grams versus 1,440 grams on average. Crucially, the high-fat animals did not waste away; they simply stopped depositing fat while presumably continuing to build lean tissue, an outcome the researchers interpret as a favorable shift in the ratio of muscle to fat.

Appetite appears to have played a central role. Although both groups were offered the same amount of feed relative to body weight, the high-fat gilts consumed significantly less, averaging 2.36 kilograms per day between days 19 and 32 compared with 3.09 kilograms in the control group. Calculated energy intake told the same story, with the control animals consuming more than 12,300 kilocalories daily against roughly 8,150 for the high-fat group. The authors suggest the animals reached satiety sooner and stopped eating, consistent with human trials reporting appetite suppression on ketogenic diets. They also caution, however, that the enormous soy hull load in the experimental diet may have contributed to early fullness or restricted digestible energy, a confound that future work should disentangle by examining fiber and fat effects on total tract digestibility directly.

Blood chemistry offered reassurance on one of the diet’s most feared risks: acidosis. Blood pH did not differ between treatments, and fasted values for sodium, bicarbonate, and carbon dioxide remained within normal reference ranges, indicating that four weeks on the high-fat regimen did not disrupt acid-base homeostasis. Urine ketone testing revealed that nutritional ketosis was largely absent, with no detectable ketones in the third week and only trace amounts, about 5 milligrams per deciliter, in three animals during the fourth. Yet the body composition changes occurred anyway, suggesting a metabolic shift away from fat storage that operated independently of measurable ketosis. One unexpected trend did emerge: fasting glucose in the high-fat group crept upward over the trial, ending significantly higher than controls at day 32, a pattern the authors tentatively link to early keto-adaptation and the liver’s efforts to protect glycogen reserves when adequate dietary protein fuels gluconeogenesis.

The microscopic analysis of the pancreas produced perhaps the most provocative data. Using immunofluorescent staining for insulin on formalin-fixed tissue sections, the researchers found that the percentage of active beta cells in the high-fat group was 2.81 times greater than in controls, 90.7 percent versus 42.4 percent, and that the area occupied by beta cells within the pancreatic islets was 1.81 times larger. Islet area as a percentage of total pancreatic tissue was also more than doubled. These findings suggest an enhancement of pancreatic architecture and insulin-producing capacity, which stands in contrast to earlier rodent studies reporting that long-term ketogenic diets can shrink beta-cell mass and impair glucose tolerance. The discrepancy may reflect species differences, the short feeding duration, or the moderate degree of ketosis actually achieved.

In skeletal muscle, the story was more selective. The researchers quantified insulin receptor presence by measuring the relative fluorescence intensity of antibody-labeled receptor proteins in cross-sections of the longissimus thoracis, the semimembranosus, and the kidney. Only the semimembranosus, a powerful muscle of locomotion in the hind limb, showed a statistically significant increase in insulin receptor density in the high-fed animals, with relative intensity of 32.8 versus 21.7 in controls. The longissimus showed a numerical but non-significant rise, and the kidney showed no difference. The authors propose that upregulated insulin receptors on muscle fibers may contribute to a muscle-sparing effect, supporting the anabolic influence of insulin on myofibrillar protein synthesis while ketone bodies spare amino acids from being diverted into gluconeogenesis. Notably, proximate analysis found no difference in crude fat content of the liver or longissimus muscle between groups, and although the high-fat animals had heavier livers relative to body weight, there was no biochemical indication of early fatty liver disease.

The researchers are candid about their limitations. The trial used only one sex, mature females, because intact males were unavailable and castrated males are considered irrelevant to human medicine, restricting generalizations to women. The ex vivo tissue analyses relied on just three biological replicates per group, and the 32-day feeding period is short by dietary-intervention standards; some human evidence suggests full metabolic benefits of ketogenic adherence may require twelve weeks or more. Statistical tendencies, including the glucose trajectory and the energy balance calculation, should be viewed with caution given the small sample size. Still, the authors argue the data provide preliminary justification for pursuing the metabolic impact of low-carbohydrate, high-fat diets on obesity using swine as a model, particularly the observation that animals lost fat mass without losing body weight.

For the millions of people experimenting with ketogenic eating, the study offers a cautiously encouraging signal wrapped in important caveats. In a tightly controlled animal model, replacing carbohydrate energy with animal fat reduced the most harmful fat depots, preserved body weight, enhanced markers of pancreatic insulin-producing capacity, and increased insulin receptor expression in a major locomotor muscle, all without measurable ketosis and without disturbing blood chemistry. Whether the same remodeling occurs in humans over months and years, and whether the fiber dilution that accompanied the high-fat ration contributed to the appetite effects, remains to be determined. What the pig study demonstrates is that the diet’s effects on body composition and insulin biology are real, measurable at the tissue level, and more nuanced than the popular narrative of ketosis alone would suggest.

Subject of Research: Effects of a low-carbohydrate, high-fat diet on muscle insulin receptor concentration and body composition in a swine biomedical model

Article Title: Does a low‐carb, high‐fat diet change muscle insulin receptor concentration and body composition in a swine biomedical model?

Article References: Acosta‐Castellanos, N., Tiede, S., Byrd, C. J., Borowicz, P., Young, J. M., & Berg, E. P. (2026). Does a low‐carb, high‐fat diet change muscle insulin receptor concentration and body composition in a swine biomedical model?. Physiological Reports, 14(19), Article e71124. https://doi.org/10.14814/phy2.71124

Image Credits: AI Generated

DOI: 10.14814/phy2.71124

Keywords: ketogenic diet, low-carbohydrate high-fat diet, insulin receptor, body composition, swine model, pancreatic beta cells, visceral fat, beef tallow, nutritional ketosis, skeletal muscle, metabolism, Physiological Reports

The biological starting point is a mismatch between how tumors and immune cells process fuel. Most cancers exhibit the Warburg effect, a heavy reliance on aerobic glycolysis even in the presence of oxygen, which generates abundant lactate, promotes extracellular acidosis, and drives redox imbalance. This metabolic environment contributes to T-cell exhaustion, creating what the review describes as a negative feedback loop between tumor metabolic plasticity and immune suppression. Modern therapies, whether checkpoint inhibitors or cytotoxic drugs, often fail not because they cannot reach the tumor, but because the tumor’s metabolic adaptations and the immunosuppressive microenvironment they create blunt sustained responses.

The ketogenic diet intervenes by sharply reducing circulating glucose and insulin while raising ketone bodies, principally β-hydroxybutyrate and acetoacetate. For glycolysis-dependent tumor cells, this creates metabolic stress: glycolytic flux falls, lactate production drops, and the flow of glycolytic intermediates into the pentose phosphate pathway is restricted, depleting the nucleotide and NADPH pools needed for DNA synthesis and antioxidant defense. Ketogenic feeding also downregulates key glycolytic enzymes such as pyruvate kinase M2 and has been shown to increase mitochondrial reactive oxygen species in tumors. Cells already stressed by hypoxia, oncogenic signaling, or replication stress may then be pushed closer to the threshold at which chemotherapy- or radiation-induced damage becomes lethal.

Crucially, the review emphasizes that this selectivity is relative rather than absolute. Normal tissues and immune cells possess greater metabolic flexibility and can switch from glucose to fatty acid and ketone oxidation. Tumors with low levels of ketolysis enzymes, such as succinyl-CoA:3-ketoacid CoA transferase, cannot efficiently use β-hydroxybutyrate or acetoacetate as oxidative fuels and remain dependent on glycolytic substrates. Some tumors, however, retain functional ketolytic pathways and can adapt to ketosis, which limits the metabolic selectivity hypothesis. The diet’s benefits, the authors argue, are most likely in tumors that are highly glucose-dependent yet cannot compensate through ketone oxidation, and patient selection will therefore hinge on characterizing each tumor’s metabolic phenotype.

Ketone bodies are not merely fuel. β-hydroxybutyrate acts as a signalling metabolite with two notable functions: it engages the hydroxycarboxylic acid receptor 2 to dampen NF-κB and NLRP3 inflammasome-mediated inflammation, and it functions as an endogenous inhibitor of class I histone deacetylases, opening chromatin and altering transcriptional programs toward stress resistance and, in some contexts, anti-tumor states. Acetyl-CoA generated during ketolysis can feed into the citric acid cycle and support histone acetylation in immune cells, directly linking metabolism to gene expression. Experimental work shows that activated CD8-positive T cells can oxidize ketones to boost mitochondrial membrane potential and TCA-cycle flux, and that impairing ketone oxidation enzymes compromises T-cell proliferation and anti-tumor activity.

On the immune side, the diet may address one of the central barriers to durable immunotherapy responses: T-cell exhaustion. In the glucose-starved tumor microenvironment, activated T cells normally compete with glycolytic tumor cells and lose effector function. Under ketogenic conditions, metabolically flexible cytotoxic lymphocytes can sustain themselves through oxidative phosphorylation, and experimental studies suggest reductions in exhaustion markers such as PD-1, TIM-3, and LAG-3 in some settings. The diet may also re-polarize tumor-associated macrophages from immunosuppressive M2-like toward inflammatory M1-like phenotypes, and by lowering lactate and acidosis it may relieve metabolic suppression of dendritic cell antigen presentation. Effects on regulatory T cells are less predictable, since Treg maintenance depends on fatty acid oxidation and local nutrient composition, so ketosis may shift the nutrient competition between Tregs and effector CD8-positive cells rather than uniformly favoring one population.

These immunometabolic effects provide a mechanistic rationale for combining the diet with checkpoint inhibitors and adoptive cell therapies. Preclinical models have shown that ketogenic interventions can improve responses to PD-1 blockade, potentially converting immunologically cold tumors into more therapy-responsive states. For CAR-T therapy in solid tumors, where hypoxia, nutrient deprivation, and chronic antigen stimulation undermine engineered T-cell survival, ketogenic states could enhance oxidative metabolism and mitochondrial robustness, promoting memory-like T-cell states that sustain long-term responses. The review also explores synergy with targeted agents: reduced insulin and IGF-1 signaling may complement PI3K/Akt/mTOR inhibitors, and combinations with metformin or IDH inhibitors are biologically plausible, though evidence for clinically meaningful benefit remains preliminary.

A third layer of the framework involves the gut microbiome. By altering nutrient availability, the ketogenic diet changes microbial community composition and metabolite production, including short-chain fatty acids such as butyrate and propionate, which support epithelial barrier integrity, promote T-cell differentiation, and inhibit histone deacetylases. Certain bacterial taxa are associated with improved T-cell activation and better outcomes during anti-PD-1 therapy, raising the possibility that diet-induced microbiome remodeling could influence immunotherapy response. The authors stress, however, that direct proof linking ketogenic microbiome changes to improved cancer treatment outcomes remains preclinical, and connections between specific microbial shifts and therapy response have not been established as causal.

The clinical evidence base lags well behind the mechanistic story. Human studies to date, largely small prospective trials, pilot studies, and retrospective observations in glioblastoma, breast cancer, and gastrointestinal tumors, have consistently demonstrated that the diet reliably changes systemic metabolism, lowering glucose and insulin signaling and raising blood ketones when nutritional ketosis is achieved. Evidence for anti-tumor efficacy, however, is inconsistent, with some reports of disease stabilization and others showing no tumor control benefit. Adherence is a major obstacle, particularly in patients experiencing anorexia, nausea, or weight loss, and nutritional ketosis itself is a non-uniform exposure, with patients on ostensibly identical diets achieving different β-hydroxybutyrate levels. The review calls for future trials to report objective measures of ketosis, dietary composition, caloric and protein intake, and predefined metabolic targets, and to develop biomarker-guided approaches that identify which tumors are metabolically vulnerable.

The overarching message is one of calibrated optimism. The ketogenic diet should not be viewed as inherently anti-carcinogenic, nor as a substitute for established cancer therapies; current evidence does not support its use as an independent curative treatment. Instead, its greatest promise may lie in creating a coordinated biological environment, low glucose and insulin, elevated ketone signalling, preserved T-cell mitochondrial fitness, reduced dysfunctional inflammation, remodeled microbiome metabolites, and altered chromatin states, in which susceptible tumors become more sensitive to the therapies already in clinical use. Until large, controlled prospective trials clarify optimal patient selection, protocols, and long-term safety, the authors conclude, ketogenic strategies should remain carefully supervised adjunctive approaches within an emerging field of precision metabolic oncology.

Subject of Research: Ketogenic diet as an immunometabolic sensitization strategy in cancer therapy

Article Title: Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation

Article References: Mannan, M. S., Khan, M. W., Haseeb Khan, M. A., Javed, A., Hussain, S. M., & Adil, H. (2026). Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation. Medical Oncology, 43(11), Article 297. https://doi.org/10.1007/s12032-026-03425-0

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03425-0

Keywords: ketogenic diet, cancer metabolism, immunotherapy, beta-hydroxybutyrate, tumor microenvironment, gut microbiome, epigenetic regulation, T-cell exhaustion, Warburg effect, checkpoint inhibitors, nutritional ketosis, precision oncology